Search Results

BioMed Diagnostics, a leader in microbiological testing and a DCN Dx brand, is pleased to announce their attendance at VMX 2024.

Mainz Biomed N.V. will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, held its annual general meeting on Friday, May 31, 2024 in Amsterdam, The Netherlands.

The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

Mainz Biomed N.V., a leader in molecular genetics diagnostic solutions for early cancer detection, announced financial results for the fiscal year ended December 31, 2023.

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, presented pivotal data from its largest cohort to date during a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois, and online.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2024 financial results and provided a business update.

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.

Mainz Biomed N.V. announced groundbreaking topline results from a pooled clinical study which included new patients and subjects from Mainz Biomed’s ColoFuture and eAArly DETECT clinical trials evaluating the potential to integrate its portfolio of proprietary novel gene expression biomarkers into a next generation version of the Company’s colorectal cancer screening tool.

Connecticut Governor Ned Lamont, New Haven Mayor Justin Elicker, and Josh Geballe, Managing Director of Yale Ventures, participated in the launch ceremony of the new BioMed X Institute on Tuesday, June 11, 2024.